VEGFA and nasopharyngeal carcinoma: Additionally, treatment of EBV-positive NPC cells with Axitinib, a selective inhibitor of VEGF receptors, did not affect in vitro VM formation (Supplementary Fig. 7c), indicating that VEGF did not contribute to the EBV-induced VM.